-
公开(公告)号：US20240181371A1
公开(公告)日：2024-06-06
申请号：US17910436
申请日：2021-03-11
Applicant: Yeda Research and Development Co. Ltd
Inventor： Ron Naaman , Francesco Tassinari , Yutao SANG , Kakali Santra , Debkumar Bhowmick
CPC classification number: B01D9/0063 , B01D9/0009 , B01D9/005 , B01D9/02 , B01D2009/0086
Abstract: The present invention relates to a technique for flow crystallization. The system comprises a container having a bottom surface defining a first plane, the container including at least two planar magnetic surfaces being arranged in a spaced-apart manner along a first plane and being substantially parallel to a second plane; a magnetization vector of each of the magnetic surfaces being perpendicularly to the surface, wherein the container is configured such that the first plane is substantially perpendicularly to the second plane; wherein a cavity formed in between the planar magnetic surfaces is configured to accommodate a racemic mixture including different enantiomers such that each magnetic surface interacts differently with each of the different enantiomers to thereby enable enantio-selective crystallization. Therefore, the system of the present invention is based on enantio-separation of the crystals using magnetic surfaces.
-
212.发明公开公开(公告)号：US20240180966A1
公开(公告)日：2024-06-06
申请号：US18384390
申请日：2023-10-27
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yardena SAMUELS , Nir FRIEDMAN , Aviyah PERI , Erez GREENSTEIN , Michal ALON
CPC classification number: A61K35/17 , A61K39/4611 , A61K2239/57
Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a population of T cells, wherein an alpha chain of a TCR of at least 10% of the T cells of the population has a CDR3 amino acid sequence as set forth in SEQ ID NO: 6, and a beta chain of the CDR has a CDR3 amino acid sequence as set forth in SEQ ID NO: 7.
-
公开(公告)号：US20240166768A1
公开(公告)日：2024-05-23
申请号：US18430696
申请日：2024-02-02
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irit SAGI , Roei David MAZOR , Ziv SHULMAN
IPC: C07K16/40 , A61K39/00 , A61K39/395 , A61P35/00 , C07K14/725 , G01N33/573 , G01N33/574
CPC classification number: C07K16/40 , A61K39/3955 , A61K39/4613 , A61P35/00 , C07K14/7051 , G01N33/573 , G01N33/57492 , C07K2319/30 , G01N2333/96486
Abstract: Monoclonal antibodies for the treatment of ovarian cancer are provided also provide are uses of same. Such uses include characterizing the tumor, diagnosing it and treatment of same.
-
214.发明公开公开(公告)号：US20240156959A1
公开(公告)日：2024-05-16
申请号：US18544514
申请日：2023-12-19
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yosef YARDEN , Ashish NORONHA
IPC: A61K39/395 , A61K31/502 , A61K31/506 , A61P35/00
CPC classification number: A61K39/3955 , A61K31/502 , A61K31/506 , A61P35/00
Abstract: A method of treating cancer in a subject in need thereof is disclosed wherein cancer cells of the subject express an EGFR having a mutation in a kinase domain of the receptor. The method comprises administering to the subject a therapeutically effective amount of: (i) an anti-epidermal growth factor receptor (anti-EGFR) antibody; (ii) an AXL inhibitor, and optionally (iii) a tyrosine kinase inhibitor (TKI). Also disclosed is a new anti-AXL antibody.
-
215.发明公开公开(公告)号：US20240148845A1
公开(公告)日：2024-05-09
申请号：US18515358
申请日：2023-11-21
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair REISNER , Noga OR-GEVA , Eran OPHIR , Yaki EIDELSTEIN , Rotem GIDRON BUDOVSKY
IPC: A61K39/00 , A61K35/17 , A61K39/395 , A61P31/00 , A61P35/04 , C07K16/28 , C12N5/078 , C12N5/0783
CPC classification number: A61K39/001 , A61K35/17 , A61K39/39566 , A61P31/00 , A61P35/04 , C07K16/2896 , C12N5/0636 , C12N5/0637 , C12N5/0648 , A61K2035/122 , A61K2039/5158 , C12N2501/2315 , C12N2501/2321 , Y02A50/30
Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.
-
Patent Agency Ranking
公开(公告)号：US11977955B2
公开(公告)日：2024-05-07
申请号：US18299792
申请日：2023-04-13
Inventor： Gil Semo , Ziv Aqua , Oded Melamed , Dan Charash , Serge Rosenblum , Barak Dayan
Abstract: A quantum computing system comprises a plurality of photonic cavities, a plurality of coupling locations for quantum emitter positioning, a photon generator configured to supply photons to the plurality of photonic cavities, and a plurality of photon output channels downstream of the plurality of cavities to output a graph state. Each coupling location is associated with a differing one of the plurality of photonic cavities. Quantum emitters associated with each coupling location are configured to mediate interactions between consecutive incoming photonic qubits to generate the graph state, and the photonic cavities are configured to couple photonic qubits to the quantum emitters.
-
217.发明授权公开(公告)号：US11965885B2
公开(公告)日：2024-04-23
申请号：US17332178
申请日：2021-05-27
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventor： Rachel Sorek , Keren Jakobi , Pennina Safer , Anat Reiner-Benaim , Irun R. Cohen
IPC: G01N33/564 , G01N33/68 , G16B40/00 , G16B40/20
CPC classification number: G01N33/564 , G01N33/6854 , G16B40/20 , G01N2800/104 , G16B40/00
Abstract: Methods and kits for diagnosing or monitoring systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing or monitoring SLE in a subject.
-
公开(公告)号：US20240127099A1
公开(公告)日：2024-04-18
申请号：US18378617
申请日：2023-10-10
Inventor： Gil SEMO , Ziv AQUA , Oded MELAMED , Dan CHARASH , Serge ROSENBLUM , Barak DAYAN
IPC: G06N10/40
CPC classification number: G06N10/40
Abstract: A quantum computing system includes a first resonator couplable to a first alkali atom, a second resonator couplable to a second alkali atom, and lasers for trapping, cooling, and manipulating the first alkali atom and the second alkali atom. Detectors detect a presence of the trapped first alkali atom and the trapped second alkali atom, and a processor is configured to receive at least one input signal from at least one of the detectors, the input signal indicating a presence of the trapped first alkali atom and the trapped second alkali atom, and, based on the received input, control at least some of the lasers to manipulate at least one of the trapped first alkali atom and the trapped second alkali atom to thereby generate photonic qubits using the trapped first alkali atom or generate entanglement between photonic qubits transmitted to the trapped second alkali atom.
-
219.发明授权公开(公告)号：US11944644B2
公开(公告)日：2024-04-02
申请号：US16769111
申请日：2018-12-04
Applicant: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Zelig Eshhar , Tova Waks , Anat Globerson Levin , Moran Rawet Slobodkin
IPC: A61K39/00 , A61K35/17 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N5/10 , C12N15/63
CPC classification number: A61K35/17 , A61K39/001126 , A61K39/001129 , A61K39/3955 , A61K39/39558 , A61K39/4631 , A61P35/00 , C07K16/28 , C07K16/2896 , C07K16/3061 , C12N5/0636 , C12N5/10 , C12N15/63 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/569 , C07K2317/76 , C07K2319/03
Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
-
公开(公告)号：US11920164B2
公开(公告)日：2024-03-05
申请号：US15500163
申请日：2015-07-30
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yaqub Hanna , Noa Novershtern , Yoach Rais
IPC: C12N5/00 , C12N5/0735 , C12N5/074
CPC classification number: C12N5/0696 , C12N5/0037 , C12N5/0606 , C12N2500/38 , C12N2500/90 , C12N2501/01 , C12N2501/115 , C12N2501/125 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/235 , C12N2501/415 , C12N2501/50 , C12N2501/60 , C12N2501/71 , C12N2501/72 , C12N2501/727 , C12N2501/73 , C12N2501/999 , C12N2506/00
Abstract: A culture medium is disclosed which comprises STAT3 activator, an ERK1/2 inhibitor and an Axin stabilizer, and optionally also a PKC inhibitor. Cell cultures comprising same and uses thereof are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
997
records
(took 0.251 seconds)
